Strides Pharma Science Limited (STAR.BO)
INR 702.0
(1.56%)
INR 702.0
(1.56%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 14.38 Billion INR | -24.55% |
| 2022 | 19.06 Billion INR | 32.53% |
| 2021 | 14.38 Billion INR | -21.91% |
| 2020 | 18.42 Billion INR | 25.1% |
| 2019 | 14.72 Billion INR | 49.18% |
| 2018 | 9.87 Billion INR | -28.05% |
| 2017 | 13.72 Billion INR | 5.21% |
| 2016 | 13.04 Billion INR | 4.54% |
| 2015 | 12.47 Billion INR | 118.47% |
| 2014 | 5.71 Billion INR | 24.77% |
| 2013 | 4.57 Billion INR | 14.38% |
| 2012 | 4 Billion INR | -67.94% |
| 2011 | 12.47 Billion INR | 71.68% |
| 2010 | 7.26 Billion INR | 32.58% |
| 2009 | 5.48 Billion INR | 26.44% |
| 2008 | 4.33 Billion INR | 32.77% |
| 2007 | 3.26 Billion INR | -8.88% |
| 2006 | 3.58 Billion INR | 26.64% |
| 2005 | 2.82 Billion INR | 27.79% |
| 2004 | 2.21 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 7.03 Billion INR | 6.63% |
| 2024 Q1 | 4.06 Billion INR | -3.0% |
| 2023 FY | 14.38 Billion INR | -24.55% |
| 2023 Q3 | 6.16 Billion INR | 6.04% |
| 2023 Q2 | 5.81 Billion INR | 6.66% |
| 2023 Q4 | 4.18 Billion INR | -32.05% |
| 2023 Q1 | 5.45 Billion INR | 26.45% |
| 2022 Q3 | 4.97 Billion INR | -2.48% |
| 2022 Q4 | 4.31 Billion INR | -13.34% |
| 2022 Q1 | 4.68 Billion INR | 51.42% |
| 2022 FY | 19.06 Billion INR | 32.53% |
| 2022 Q2 | 5.1 Billion INR | 8.87% |
| 2021 Q3 | 3.93 Billion INR | -0.89% |
| 2021 Q1 | 3.39 Billion INR | -14.38% |
| 2021 Q2 | 3.96 Billion INR | 16.95% |
| 2021 Q4 | 3.09 Billion INR | -21.34% |
| 2021 FY | 14.38 Billion INR | -21.91% |
| 2020 Q3 | 4.81 Billion INR | -0.76% |
| 2020 FY | 18.42 Billion INR | 25.1% |
| 2020 Q2 | 4.85 Billion INR | 1.16% |
| 2020 Q4 | 3.96 Billion INR | -17.69% |
| 2020 Q1 | 4.79 Billion INR | 122.77% |
| 2019 Q2 | 4.16 Billion INR | 12.5% |
| 2019 Q4 | 2.15 Billion INR | -54.33% |
| 2019 Q1 | 3.69 Billion INR | 13.97% |
| 2019 FY | 14.72 Billion INR | 49.18% |
| 2019 Q3 | 4.71 Billion INR | 13.26% |
| 2018 Q3 | 2.89 Billion INR | 11.5% |
| 2018 FY | 9.87 Billion INR | -28.05% |
| 2018 Q4 | 3.24 Billion INR | 12.05% |
| 2018 Q2 | 2.59 Billion INR | 20.27% |
| 2018 Q1 | 2.16 Billion INR | -41.83% |
| 2017 Q2 | 3.82 Billion INR | 24.61% |
| 2017 Q3 | 3.99 Billion INR | 4.5% |
| 2017 Q4 | 3.71 Billion INR | -7.09% |
| 2017 Q1 | 3.06 Billion INR | -20.38% |
| 2017 FY | 13.72 Billion INR | 5.21% |
| 2016 Q2 | 4.98 Billion INR | 19.55% |
| 2016 FY | 13.04 Billion INR | 4.54% |
| 2016 Q3 | 3.85 Billion INR | -22.59% |
| 2016 Q4 | 3.85 Billion INR | 0.02% |
| 2016 Q1 | 4.16 Billion INR | -5.25% |
| 2015 FY | 12.47 Billion INR | 118.47% |
| 2015 Q2 | 3.34 Billion INR | 20.1% |
| 2015 Q4 | 4.39 Billion INR | 8.18% |
| 2015 Q3 | 4.06 Billion INR | 21.65% |
| 2015 Q1 | 2.78 Billion INR | 69.43% |
| 2014 Q3 | 1.54 Billion INR | 14.4% |
| 2014 FY | 5.71 Billion INR | 24.77% |
| 2014 Q2 | 1.34 Billion INR | 14.26% |
| 2014 Q1 | 1.18 Billion INR | 0.0% |
| 2014 Q4 | 1.64 Billion INR | 6.36% |
| 2013 FY | 4.57 Billion INR | 14.38% |
| 2012 FY | 4 Billion INR | -67.94% |
| 2011 FY | 12.47 Billion INR | 71.68% |
| 2010 FY | 7.26 Billion INR | 32.58% |
| 2009 FY | 5.48 Billion INR | 26.44% |
| 2008 FY | 4.33 Billion INR | 32.77% |
| 2007 FY | 3.26 Billion INR | -8.88% |
| 2006 FY | 3.58 Billion INR | 26.64% |
| 2005 FY | 2.82 Billion INR | 27.79% |
| 2004 FY | 2.21 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 31.693% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -824.37% |
| Sigachi Industries Limited | 2 Billion INR | -618.585% |
| Bal Pharma Limited | 770.19 Million INR | -1768.113% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | -132.278% |
| Medico Remedies Limited | 262.14 Million INR | -5388.628% |
| Lasa Supergenerics Limited | 121.02 Million INR | -11788.053% |
| Venus Remedies Limited | 2.18 Billion INR | -559.223% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 2488.441% |
| Alpa Laboratories Limited | 188.89 Million INR | -7516.988% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -384.112% |
| Shilpa Medicare Limited | 3.54 Billion INR | -305.658% |
| Aarti Drugs Limited | 8.31 Billion INR | -73.013% |
| Lupin Limited | 123.71 Billion INR | 88.37% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 90.698% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 88.509% |
| Windlas Biotech Limited | 1.33 Billion INR | -974.702% |
| Suven Life Sciences Limited | -200.79 Million INR | 7265.5% |
| Eris Lifesciences Limited | 10.42 Billion INR | -37.992% |
| Valiant Laboratories Limited | -60.66 Million INR | 23817.707% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 36.616% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -1570.705% |
| Ipca Laboratories Limited | 29.8 Billion INR | 51.734% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -289.348% |
| Achyut Healthcare Limited | 4.86 Million INR | -295890.743% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 94.434% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -877.582% |
| RPG Life Sciences Limited | 2.48 Billion INR | -479.465% |
| Mankind Pharma Limited | 44.52 Billion INR | 67.682% |
| Laurus Labs Limited | 24.62 Billion INR | 41.559% |
| Piramal Pharma Limited | 24.47 Billion INR | 41.203% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -1426.754% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 69.228% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 46.274% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 79.25% |
| Unichem Laboratories Limited | 4.86 Billion INR | -195.752% |
| Sequent Scientific Limited | 2.97 Billion INR | -383.028% |
| Novartis India Limited | 1.32 Billion INR | -984.34% |
| Wanbury Limited | 1.73 Billion INR | -731.374% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -248.949% |
| Wockhardt Limited | 16.24 Billion INR | 11.403% |
| Themis Medicare Limited | 1.5 Billion INR | -856.717% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -2104.77% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 26.752% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | -15.725% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 91.206% |
| Divi's Laboratories Limited | 32.44 Billion INR | 55.647% |
| NATCO Pharma Limited | 25.73 Billion INR | 44.093% |
| Gufic Biosciences Limited | 4.16 Billion INR | -245.229% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -214.096% |
| Ind-Swift Limited | 2.17 Billion INR | -562.274% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -148.869% |
| FDC Limited | 8.33 Billion INR | -72.628% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -7365.539% |
| Granules India Limited | 16.79 Billion INR | 14.353% |
| Medicamen Biotech Limited | 495.49 Million INR | -2803.785% |
| Alkem Laboratories Limited | 52.29 Billion INR | 72.488% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | -131.22% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -98585.913% |
| Brooks Laboratories Limited | 65.62 Million INR | -21826.41% |
| Megasoft Limited | 342.07 Million INR | -4106.176% |
| ZIM Laboratories Limited | 1.26 Billion INR | -1035.706% |
| Neuland Laboratories Limited | 8.24 Billion INR | -74.447% |
| Morepen Laboratories Limited | 6.16 Billion INR | -133.525% |
| Hikal Limited | 3.14 Billion INR | -357.771% |
| Indoco Remedies Limited | 6.04 Billion INR | -138.162% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -146.737% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -2218.879% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -1944.913% |
| Hester Biosciences Limited | 1.27 Billion INR | -1029.675% |